title: Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.
abstract: BACKGROUND
  Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined.
  
  
  METHODS
  Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs.
  
  
  RESULTS
  Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients.
  
  
  CONCLUSIONS
  The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.
authors.affiliation: Lymphoma Group, Molecular Pathology Programme Spanish National Cancer Research Centre, CNIO, Madrid, Spain. smontes@cnio.es
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.forename: Ana-Rosa
authors.initials: AR
authors.lastname: Gonzalez-Medina
authors.forename: Socorro-María
authors.initials: SM
authors.lastname: Rodriguez-Pinilla
authors.forename: Lorena
authors.initials: L
authors.lastname: Maestre
authors.forename: Lydia
authors.initials: L
authors.lastname: Sanchez-Verde
authors.forename: Giovanna
authors.initials: G
authors.lastname: Roncador
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.forename: Juan F
authors.initials: JF
authors.lastname: García
authors.forename: Javier
authors.initials: J
authors.lastname: Menarguez
authors.forename: Carlos
authors.initials: C
authors.lastname: Montalbán
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Ruiz-Marcellan
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002454:Cell Differentiation; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D051757:PAX5 Transcription Factor / Q000378:metabolism; D010950:Plasma Cells / Q000737:chemistry* / Q000187:drug effects / Q000473:pathology; D000074462:Positive Regulatory Domain I-Binding Factor 1; D012097:Repressor Proteins / Q000378:metabolism; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018951:Antigens, CD20; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; D012097:Repressor Proteins; C087042:PRDM1 protein, human; D000074462:Positive Regulatory Domain I-Binding Factor 1